The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?

被引：52

作者：

Eskens, Ferry A. L. M. ^{[1
]}

Sleijfer, Stefan ^{[1
]}

机构：

[1] Erasmus Univ, Med Ctr, Dept Med Oncol, NL-3000 CA Rotterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2008年 / 44卷 / 16期

关键词：

Bevacizumab; Treatment; Cancer;

D O I：

10.1016/j.ejca.2008.07.042

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bevacizumab is approved for the treatment of colorectal cancer, breast cancer, non-small cell lung cancer and renal cell cancer. Before embracing this expensive agent for many other indications, it remains critical to be aware of the evidence upon which oncologists base their day-to-day clinical practice. In this review, we address the results of clinical studies upon which bevacizumab's current use is based and discuss some future perspectives. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：2350 / 2356

页数：7

共 25 条

[1] ALLEGRA C, 2008, J CLIN ONCOL S, V26
[2] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Burger, Robert A.
Sill, Michael W.
Monk, Bradley J.
Greer, Benjamin E.
Sorosky, Joel I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
[3] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Cannistra, Stephen A.
Matulonis, Ursula A.
Penson, Richard T.
Hambleton, Julie
Dupont, Jakob
Mackey, Howard
Douglas, Jeffrey
Burger, Robert A.
Armstrong, Deborah
Wenham, Robert
McGuire, William
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5180 - 5186
[4] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Escudier, Bernard
Pluzanska, Anna
Koralewski, Piotr
Ravaud, Alain
Bracarda, Sergio
Szczylik, Cezary
Chevreau, Christine
Filipek, Marek
Melichar, Bohuslav
Bajetta, Emilio
Gorbunova, Vera
Bay, Jacques-Olivier
Bodrogi, Istvan
Jagiello-Gruszfeld, Agnieszka
Moore, Nicola
[J]. LANCET, 2007, 370 (9605) : 2103 - 2111
[5] FOREROTORRES A, 2008, J CLIN ONCOL S, V26
[6] Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Garcia, Agustin A.
Hirte, Hal
Fleming, Gini
Yang, Dongyun
Tsao-Wei, Denice D.
Roman, Lynda
Groshen, Susan
Swenson, Steve
Markland, Frank
Gandara, David
Scudder, Sidney
Morgan, Robert
Chen, Helen
Lenz, Heinz-Josef
Oza, Amit M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 76 - 82
[7] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Giantonio, Bruce J.
Catalano, Paul J.
Meropol, Neal J.
O'Dwyer, Peter J.
Mitchell, Edith P.
Alberts, Steven R.
Schwartz, Michael A.
Benson, Al B., III
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) : 1539 - 1544
[8] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Hurwitz, H
Fehrenbacher, L
Novotny, W
Cartwright, T
Hainsworth, J
Heim, W
Berlin, J
Baron, A
Griffing, S
Holmgren, E
Ferrara, N
Fyfe, G
Rogers, B
Ross, R
Kabbinavar, F
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2335 - 2342
[9] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
Kabbinavar, F
Hurwitz, HI
Fehrenbacher, L
Meropol, NJ
Novotny, WF
Lieberman, G
Griffing, S
Bergsland, E
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 60 - 65
[10] Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
Kabbinavar, FF
Schulz, J
McCleod, M
Patel, T
Hamm, JT
Hecht, JR
Mass, R
Perrou, B
Nelson, B
Novotny, WF
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3697 - 3705

← 1 2 3 →